Document Detail


Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.
MedLine Citation:
PMID:  23322644     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONCLUSION: Mutations conferring partial resistance to SIL treatment in vivo and in cell culture argue for a mechanism involving NS4B. This novel mode of action renders SIL an attractive candidate for combination therapies with other directly acting antiviral drugs, particularly in difficult-to-treat patient cohorts.
Authors:
Katharina Esser-Nobis; Inés Romero-Brey; Tom M Ganten; Jérôme Gouttenoire; Christian Harak; Rahel Klein; Peter Schemmer; Marco Binder; Paul Schnitzler; Darius Moradpour; Ralf Bartenschlager; Stephen J Polyak; Wolfgang Stremmel; François Penin; Christoph Eisenbach; Volker Lohmann
Related Documents :
23063764 - Hiv/hpv co-infection during pregnancy in southeastern brazil: prevalence, hpv types, cy...
23039894 - B cell activating factor (baff) in the natural history of chronic hepatitis c virus liv...
23157424 - Genital immunology and hiv susceptibility in young women.
24070654 - Dancing with chemical formulae of antivirals: a panoramic view (part 2).
11352244 - Systemic lupus erythematosus in adults is associated with previous epstein-barr virus e...
16476684 - Prevention of mother-to-child transmission of hiv infection: ukraine experience to date.
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2013-02-07
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  57     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-03-04     Completed Date:  2013-04-23     Revised Date:  2014-03-06    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  953-63     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 American Association for the Study of Liver Diseases.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antioxidants / pharmacology,  therapeutic use
Antiviral Agents / pharmacology,  therapeutic use
Cells, Cultured
Drug Resistance, Viral / genetics*
Genotype
Hepacivirus / drug effects*,  genetics*
Hepatitis C, Chronic / drug therapy*,  virology
Humans
Male
Phenotype
Silymarin / pharmacology*,  therapeutic use
Viral Nonstructural Proteins / genetics*
Virus Replication / drug effects,  genetics
Grant Support
ID/Acronym/Agency:
R01 AT006842/AT/NCCAM NIH HHS; R01AT006842/AT/NCCAM NIH HHS; R56 AI091840/AI/NIAID NIH HHS; R56AI091840./AI/NIAID NIH HHS; U19AI066328/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Antioxidants; 0/Antiviral Agents; 0/NS3 protein, hepatitis C virus; 0/NS4B protein, flavivirus; 0/Silymarin; 0/Viral Nonstructural Proteins; 4RKY41TBTF/silybin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Testing and reporting practices for improved management of hepatitis C.
Next Document:  Rapid parameter optimization of low signal-to-noise samples in NMR spectroscopy using rapid CPMG pul...